TY - JOUR T1 - The influence of roflumilast on the IV-type collagen level in patients with III stage COPD JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P3775 AU - Mykola Ostrovskyy AU - Oleksandr Varunkiv AU - Iryna Savelikhina AU - Mariana Kulynych-Miskiv Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P3775.abstract N2 - Background. Chronic obstructive pulmonary diseases are diagnosed in 4-6 % of men and 1-3 %of women above 40 years old. The persistent inflammatory process in bronchi, the development ofmicrocirculation disorders, the increasing of hypoxia processes result in the activation of fibroblastsand their production of IV-type collagen, which is manifested by the formation of peribronchialpneumosclerosis.Purpose of the study: the evaluation of the IV-type collagen level dynamics in BALF of patients with 3rdstage COPD during the treatment with Roflumilast.Materials and methods: The contents of the IV-type collagen in BALF was evaluated in 39 patients with III stage COPD in a relapse stage using enzyme-linked immunosorbent assay before and after 3 months of treatment with the inhibitor of phosphodiesterase -4 – Roflumilast, 500 mg per day, inside, together with the basic 3rd stage COPD treatment (GOLD, 2010).Results of the study: The contents of the IV-type collagen in BALF before the beginning of treatment inpatients with 3rd stage COPD was (69.13±3.12) ng / ml, which is in 7,14 times higher than in almost healthy people,whose contents constituted (9,68±0,54) ng / ml. After the second examination in 90 days, the above –mentioned indicator in patients fell down by 2,45 times and was equal (28,26±2,23) ng / ml.Conclusions: The depression of IV-type collagen levels demonstrate the ability to slow down pneumosclerosis progression in patients with III COPD who are treated with Roflumilast. ER -